1
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
2
Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: Ovarian cancer comprises a heterogeneous group of neoplasms. The prognosis cannot be predicted by histopathologic examination alone. The aim of this study is to evaluate p53, PTEN, and β-catenin expressions in primary ovarian carcinomas in an attempt to find a possible relationship with morphologic parameters and clinical findings.Methods: The study included 100 epithelial ovarian tumors (borderline and carcinomas) from affiliated hospitals of Shiraz university of medical sciences during 2007-2013. Immunohistochemical staining for p53, PTEN, and β-catenin was performed on 65 serous, 18 mucinous, 10 endometrioid, 5 clear cell, and 2 mixed tumors.Results: p53 expression pattern in serous carcinoma significantly differed from endometrioid carcinomas. Strong positivity (2+) in >50% of the tumor cells favored serous carcinoma. PTEN expression significantly differed in mucinous and serous carcinomas as well as in endometrioid carcinoma and borderline endometrioid tumor. There was significantly decreased β-catenin expression in the carcinomas compared with borderline tumors. In all of the different subtypes of ovarian carcinomas, we observed a significant association with decreased β-catenin expression to tumor grade as well as in serous carcinomas with increased nuclear grade, mitosis, and tumor grade. There was no significant relation between expressions of p53, PTEN, and β-catenin in epithelial ovarian tumors to FIGO staging, response to chemotherapy, serum CA- 125 marker, and tumor recurrence.Conclusion: p53 and PTEN are helpful in differentiation of some epithelial ovarian tumor subtypes. In serous carcinomas, diminished expression of β-catenin is associated with higher tumor and nuclear grade. This expression is significantly different in borderline and carcinomas.
Sari Aslani, F., Momeni, A., Momtahan, M., Akbarzadeh Jahromi, M., Dehghanian, A. R. & Motevali, D. (2015). Evaluation of p53, PTEN and β-catenin Immunoexpressions in Primary Ovarian Epithelial Tumors. Middle East Journal of Cancer, 6(3), 135–142.
MLA
Sari Aslani, F., Momeni, A., Momtahan, M., Akbarzadeh Jahromi, M., Dehghanian, A. R., & Motevali, D. "Evaluation of p53, PTEN and β-catenin Immunoexpressions in Primary Ovarian Epithelial Tumors", Middle East Journal of Cancer, 6, 3, 2015, 135–142.
HARVARD
Sari Aslani, F., Momeni, A., Momtahan, M., Akbarzadeh Jahromi, M., Dehghanian, A. R., & Motevali, D. (2015). 'Evaluation of p53, PTEN and β-catenin Immunoexpressions in Primary Ovarian Epithelial Tumors', Middle East Journal of Cancer, 6(3), pp. 135–142.
CHICAGO
Sari Aslani, F., Momeni, A., Momtahan, M., Akbarzadeh Jahromi, M., Dehghanian, A. R. & Motevali, D., "Evaluation of p53, PTEN and β-catenin Immunoexpressions in Primary Ovarian Epithelial Tumors." Middle East Journal of Cancer, 6 3 (2015): 135–142,
VANCOUVER
Sari Aslani F., Momeni A., Momtahan M., Akbarzadeh Jahromi M., Dehghanian A. R., Motevali D. Evaluation of p53, PTEN and β-catenin Immunoexpressions in Primary Ovarian Epithelial Tumors. Middle East Journal of Cancer. 2015;6(3):135–142.